Novel phenoxyalkylcarboxylic acid derivatives as hypolipidaemic agents

References

• Anum EA, Adera T. Hypercholesterolemia and coronary heart disease in the elderly: a meta-analysis. Ann Epidemiol 2004;14:705–721.
   PubMed Web of Science ®Google Scholar
• Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997;46:1319–1327.
   PubMed Web of Science ®Google Scholar
• Banner CD, Göttlicher M, Widmark E, Sjövall J, Rafter JJ, Gustafsson JA. A systematic analytical chemistry/cell assay approach to isolate activators of orphan nuclear receptors from biological extracts: characterization of peroxisome proliferator-activated receptor activators in plasma. J Lipid Res 1993;34:1583–1591.
   PubMed Web of Science ®Google Scholar
• Chong PH, Bachenheimer BS. Current, new and future treatments in dyslipidaemia and atherosclerosis. Drugs 2000;60:55–93.
   PubMed Web of Science ®Google Scholar
• Brown PJ, Winegar DA, Plunket KD, Moore LB, Lewis MC, Wilson JG et al. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity. j Med Chem 1999;42:3785–3788.
   PubMed Web of Science ®Google Scholar
• Bunnelle WH, Dart MJ, Schrimpf MR. Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity. Curr Top Med Chem 2004;4:299–334.
   PubMed Web of Science ®Google Scholar
• Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421–424.
   PubMed Web of Science ®Google Scholar
• Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527–550.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001;3:83–92.
   PubMedGoogle Scholar
• Shek A, Ferrill MJ. Statin–fibrate combination therapy. Ann Pharmacother 2001;35:908–917.
   PubMed Web of Science ®Google Scholar
• Adverse Drug Reactions Advisory Committee. Risk factors for myopathy and rhabdomyolysis with the statins. Aust Adv Drug React Bull 2004;23:2.
   Google Scholar
• Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120–122.
   PubMed Web of Science ®Google Scholar
• Laboratoires Fournier SA. Lipidil (Fenofibrate) Product Information, 13 October 2003.
   Google Scholar
• Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997;18:2029–2033.
   PubMed Web of Science ®Google Scholar
• Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088–2093.
   PubMed Web of Science ®Google Scholar
• Jeremy PES. Flavonoids: modulators of brain function? Br J Nutr 2008;99:ES60–ES77.
   Google Scholar
• Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents 2005;26:343–356.
   PubMed Web of Science ®Google Scholar
• “Studies force new view on biology of flavonoids”, by David Stauth, EurekAlert!. Adapted from a news release issued by Oregon State University. URL accessed.
   Google Scholar
• Alan L, Miller ND. Antioxidant flavonoids: structure, function and clinical usage. Altern Med Rev 1996;1:103–111.
   Google Scholar
• Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 2001;276:22586–22594.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Okuda H, Arichi S. Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim Biophys Acta 1985;834:275–278.
   PubMed Web of Science ®Google Scholar
• Mannila E, Talvitie A, Kolehmainen E. Xanthone O-glycosides from Polygala tenuifolia. Phytochemistry 1993;33:813–816.
   Web of Science ®Google Scholar
• Mahady GB, Pendland SL, Chadwick LR. Resveratrol and red wine extracts inhibit the growth of CagA+ strains of Helicobacter pylori in vitro. Am J Gastroenterol 2003;98:1440–1441.
   PubMed Web of Science ®Google Scholar
• Creasy LL, Coffee M. Phytoalexin production potential of grape berries. J Am Soc Hortic Sci 1988;113:230–234.
   Web of Science ®Google Scholar
• Chung MI, Teng CM, Cheng KL, Ko FN, Lin CN. An antiplatelet principle of Veratrum formosanum. Planta Med 1992;58:274–276.
   PubMed Web of Science ®Google Scholar
• Inamori Y, Kubo M, Tsujibo H, Ogawa M, Saito Y, Miki Y et al. The ichthyotoxicity and coronary vasodilator action of 3,3′-dihydroxy-alpha,beta-diethylstilbene. Chem Pharm Bull 1987;35:887–890.
   Google Scholar
• Schneider Y, Duranton B, Gossé F, Schleiffer R, Seiler N, Raul F. Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 2001;39:102–107.
   PubMed Web of Science ®Google Scholar
• Hegsted DM, Ausman LM. Diet, alcohol and coronary heart disease in men. J Nutr 1988;118:1184–1189.
   PubMed Web of Science ®Google Scholar
• Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992;339:1523–1526.
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5:493–506.
   PubMed Web of Science ®Google Scholar
• Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet 1993;341:1103–1104.
   PubMed Web of Science ®Google Scholar
• Ungvari Z, Orosz Z, Rivera A, Labinskyy N, Xiangmin Z, Olson S et al. Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol 2007;292:H2417–H2424.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zou J, Huang Y, Cao K, Xu Y, Wu JM. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J 2002;115:378–380.
   PubMed Web of Science ®Google Scholar
• Arichi H, Kimura Y, Okuda H, Baba K, Kozawa M, Arichi S. Effects of stilbene components of the roots of Polygonum cuspidatum Sieb. et Zucc. on lipid metabolism. Chem Pharm Bull 1982;30:1766–1770.
   PubMed Web of Science ®Google Scholar
• Rimando AM, Nagmani R, Feller DR, Yokoyama W. Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J Agric Food Chem 2005;53:3403–3407.
   PubMed Web of Science ®Google Scholar
• Li Z, Liao C, Ko BC, Shan S, Tong EH, Yin Z et al. Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators. Bioorg Med Chem Lett 2004;14:3507–3511.
   PubMed Web of Science ®Google Scholar
• Sierra ML, Beneton V, Boullay AB, Boyer T, Brewster AG, Donche F et al. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem 2007;50:685–695.
   PubMed Web of Science ®Google Scholar
• Mizuno CS, Ma G, Khan S, Patny A, Avery MA, Rimando AM. Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARalpha. Bioorg Med Chem 2008;16:3800–3808.
   PubMed Web of Science ®Google Scholar
• Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci usa 2001;98:13919–13924.
   PubMed Web of Science ®Google Scholar